EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Grading and staging for pituitary neuroendocrine tumors

Chiara Villa iD, Maria Francesca Birtolo, Luis Gustavo Perez-Rivas, Alberto Righi, Guillaume Assie, Bertrand Baussart, Sofia Asioli

Brain Pathology · 2025-01 · 35 (1)

DOI: 10.1111/bpa.13299 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain Pathology, online erschienen am 25.08.2024. Verfasst von Chiara Villa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropathology, Hôpital Universitaire Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pituitary Neoplasms, Neoplasm Grading, Neoplasm Staging. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pituitary adenoma/pituitary neuroendocrine tumors (PitNETs) are the second most common primary intracranial tumor and the most frequent neuroendocrine tumors/neoplasms of the human body. Thus, they are one of the most frequent diagnoses in neuropathologist's practise. 2022 5th edition WHO Classification of Endocrine and Neuroendocrine Tumors does not support a grading and/or staging system for PitNETs and argues that histological typing and subtyping are more robust than proliferation rate and invasiveness to stratify tumors. Numerous studies suggest the existence of clinically relevant molecular subgroups encouraging an integrated histo‐molecular approach to the diagnosis of PitNETs to deepen the understanding of their biology and overcome the unresolved problem of grading system. The present review illustrates the main issues involved in establishing a grading and a staging system, as well as alternative systems validated by independent series to date. The state of art of the current histological and molecular markers is detailed, demonstrating that a standardized and reproducible clinico‐pathological approach, combined with the integration of molecular data may help build a workflow to refine the definition of PitNETs with ‘malignant potential’ and most importantly, avoid delay in patient treatment. Next molecular studied are needed to validate an integrated histo‐molecular grading for PitNETs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPituitary NeoplasmsNeoplasm GradingNeoplasm StagingHumansAdenoma

Stichwörter der Autor:innen

EPPGPitNETsWHO classificationgradingpituitary adenomastaging

Autor:innen und Institutionen

  • Department of Neuropathology, Hôpital Universitaire Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France.
  • Inserm U1016, CNRS UMR 8104, Institut Cochin, Université Paris Descartes-Université de Paris, Paris, France.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Endocrinology, Diabetology and Medical Andrology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Medizinische Klinik und Poliklinik IV, LMU Klinikum, LMU München, Munich, Germany.
  • Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

ORCID-Profile: Chiara Villa

Zitieren

APA

Villa, C., Birtolo, M. F., Perez-Rivas, L. G., Righi, A., Assie, G., Baussart, B., & Asioli, S. (2025). Grading and staging for pituitary neuroendocrine tumors. Brain Pathology, 35(1). https://doi.org/10.1111/bpa.13299

Vancouver

Villa C, Birtolo MF, Perez-Rivas LG, Righi A, Assie G, Baussart B, et al. Grading and staging for pituitary neuroendocrine tumors. Brain Pathology. 2025;35(1). doi:10.1111/bpa.13299

BibTeX
@article{Villa2025,
  author = {Villa, Chiara and Birtolo, Maria Francesca and Perez-Rivas, Luis Gustavo and Righi, Alberto and Assie, Guillaume and Baussart, Bertrand and Asioli, Sofia},
  title = {Grading and staging for pituitary neuroendocrine tumors},
  journal = {Brain Pathology},
  year = {2025},
  volume = {35},
  number = {1},
  doi = {10.1111/bpa.13299}
}
Kostenlos starten →